Recent results also indicate that SHIP1 promotes phagolysosomal degradation of lipids by microglia, suggesting that the enzyme may be a target for the treatment of Alzheimer’s disease. This evidence concerns the gene INPP5D and early-onset autosomal dominant Alzheimer disease.